Experience

Mabwell Bioscience Announces Formation of Kalexo Bio With Aditum Bio

September 17, 2025

Cooley advised Mabwell Bioscience, an innovation-driven biopharmaceutical company with capabilities spanning the entire pharmaceutical value chain, on its exclusive license agreement with Aditum Bio to launch Kalexo Bio, a new company formed in conjunction with an exclusive global license agreement to develop 2MW7141, a novel dual-target small interfering RNA (siRNA) candidate for lipid management in patients with dyslipidemia and for the prevention of high-risk atherosclerotic cardiovascular disease events.

Read more

Related contacts

Charity Williams
Partner, San Diego
Freddy Yip
Associate, Hong Kong
Ken Rollins
Partner in Charge – San Diego, San Diego
Brett Dovman
Associate, San Diego
Jeffrey J. Tolin
Partner, New York
Amanda Pacheco
Associate, Palo Alto
Andrew Epstein
Special Counsel, Seattle
Zhijing Yu
Associate, Singapore
Christopher Kimball
Partner, Washington, DC
David Burns
Special Counsel, Washington, DC
Robert Eisenbach
Of Counsel, San Francisco
Rachel Thorn
Of counsel, New York
Natasha Leskovsek
Of Counsel, Washington, DC
Karen Tsai
Special Counsel, Washington, DC

Related Practices & Industries

Mission Secure Sells to ServiceNow

November 6, 2024

Cooley advised Mission Secure, a company focused on providing asset discovery for operational technology devices, on its sale to ServiceNow. Partner Matt Browne led the Cooley team advising Mission Secure.

Related contacts

Matt Browne
Partner, San Diego
Brett Dovman
Associate, San Diego
Pauline Le
Associate, San Diego
David H. Zhou
Associate, Palo Alto
Scott McCall
Partner, San Diego
Jeffrey J. Tolin
Partner, New York
Ross Eberly
Partner, Santa Monica
Charles Haley
Partner, Palo Alto
Umer Chaudhry
Associate, Washington, DC
Karen Tsai
Special Counsel, Washington, DC

Related Practices & Industries

TriSalus Life Sciences Completes Merger With MedTech Acquisition Corporation

August 16, 2023

Cooley advised TriSalus Life Sciences, an oncology company with a focus on treatments for patients with liver and pancreatic tumors, on its merger with MedTech Acquisition Corporation.

Read more

Related contacts

Matt Browne
Partner, San Diego
Rama Padmanabhan
Partner, San Diego
Rajdeep Roger Bains
Associate, San Diego
Alexander Gefter
Associate, Santa Monica
Brett Dovman
Associate, San Diego
Pitrina Gilger
Associate, San Diego
Carlos Ramirez
Partner, San Diego
Mischi a Marca
Partner, San Francisco
Matthew S. Scarano
Associate, San Diego
Margaret Barreto
Associate, San Francisco
Jeffrey J. Tolin
Partner, New York
Patrick Sharma
Associate, Santa Monica
Alessandra Murata
Partner, Palo Alto
Ryan Montgomery
Partner, Boston
Sharon Connaughton
Special Counsel, Washington, DC
Natasha Leskovsek
Of Counsel, Washington, DC
Natasha Leskovsek
Of Counsel, Washington, DC
Phil Mitchell
Partner, New York
Francis Wheeler
Senior Counsel, Colorado
Howard Morse
Senior Counsel, Washington, DC
Madison (JJ) Meng
Associate, San Francisco
Sarah Sellers
Partner, New York
Vince Sampson
Special Counsel, Washington, DC
Darren DeStefano
Partner, Reston
Darren DeStefano
Partner, Reston
Charity Williams
Partner, San Diego
Grady Chang
Associate, Santa Monica
Ross Eberly
Partner, Santa Monica
Kate Walther
Paralegal Specialist, San Diego

Related Practices & Industries

NKGen Biotech Announces Merger With Graf Acquisition Corp. IV

April 28, 2023

Cooley advised NKGen Biotech, a clinical-stage biotechnology company, on its business combination agreement with special purpose acquisition company Graf Acquisition Corp. IV – a combination that will result in NKGen becoming a publicly listed company.

Read more

Related contacts

Rama Padmanabhan
Partner, San Diego
Ken Rollins
Partner in Charge – San Diego, San Diego
Rajdeep Roger Bains
Associate, San Diego
Brett Dovman
Associate, San Diego
Dylan Kornbluth
Associate, San Diego
Madison (JJ) Meng
Associate, San Francisco
Sharon Connaughton
Special Counsel, Washington, DC
Megan Drill
Associate, San Diego
Ross Eberly
Partner, Santa Monica
Rick Jantz
Associate, Santa Monica
Christopher Kimball
Partner, Washington, DC
Allison Kutner
Associate, New York
Eileen Leman
Associate, Los Angeles
Natasha Leskovsek
Of Counsel, Washington, DC
Barbara Mirza
Partner, Santa Monica
Michael Shen
Special Counsel, Shanghai
Jeffrey J. Tolin
Partner, New York
Karen Tsai
Special Counsel, Washington, DC
Charity Williams
Partner, San Diego

Related Practices & Industries

Ambrx Biopharma – $126 Million IPO

June 18, 2021

Cooley advised Ambrx Biopharma on its $126 million initial public offering of 7,000,000 American depositary shares, each representing seven ordinary shares. Ambrx Biopharma, whose securities now trade on the New York Stock Exchange under the symbol AMAM, is a clinical-stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop engineered precision biologics. Partners Charlie Kim, Patrick Loofbourrow, Sean Clayton and Will Cai led the Cooley team.

Related contacts

Charlie Kim
Partner, San Diego
Patrick Loofbourrow
Partner, Singapore
Will Cai
Partner, Hong Kong
Brett Dovman
Associate, San Diego

Related Practices & Industries

View more

Admissions and credentials

New York

California

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.